ClinicalTrials.gg
RecruitingNCT06104566Updated Jun 18, 2026

Global Trial in APG2575 for Patients With CLL/SLL

A Phase 3 interventional study of lisaftoclax +BTK inhibitor and BTK inhibitor in CLL/SLL, sponsored by Ascentage Pharma Group Inc.. Recruiting at 135 sites in 19 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Read the detailed description

Approximately 440 patients will be enrolled, the patients who meet the eligibility criteria will be randomized in a 1:1 ratio to investigational arm (lisaftoclax in combination with a BTK inhibitor) or the control arm (BTK inhibitor alone). These patients with CLL/SLL have been on BTKi monotherapy and meet all other protocol required eligibility criteria.

02

Conditions studied

  • CLL/SLL
03

In context

Lead sponsor

Ascentage Pharma Group Inc. is the lead sponsor of 53 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BTKi monotherapy for at least 12 months
  3. Performance Status grade 0-2
  4. Adequate bone marrow function independent of growth factor or transfusion support within 2 weeks of screening initiation as follows:

    • ≥ 1.0 × 109/L
    • counts ≥ 75 × 109/L; in cases of thrombocytopenia
    • Total ≥ 9 g/dL,
  5. Adequate renal function

    • must be > 50 ml/min directly measured with 24hr urine collection or calculated according to the modified formula of Cockcroft and Gault (for men: ≈ ((140 - age) x actual body weight)/(72 x creatinine), for women x 0.85) or an equally accurate method.
    • For patients with creatinine values within the normal range, the calculation of clearance is not necessary. Dehydrated patients with an estimated creatinine clearance less than 50 ml/min may be eligible if a repeat estimate after adequate hydration is > 50 ml/min.
  6. Adequate liver function as indicated by:

    • Total ≤ 1.5 x , except patients with known Gilbert's Syndrome
    • (AST) ≤ 2.5 x the institutional ULN value
    • Alanine aminotransferase (ALT) ≤ 2.5 x the institutional ULN value,
    • (INR), Prothrombin Time (PT) or Activated Partial Thromboplastin time (APTT) ≤ 1.5×ULN.
  7. Ability and willingness to provide written and to adhere to the study visit schedule and other protocol requirements
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Arm 1

    Combination therapy

    Drug: lisaftoclax +BTK inhibitor

  • Active comparator
    Arm 2

    mono therapy

    Drug: BTK inhibitor

Interventions

  • Druglisaftoclax +BTK inhibitor

    Drug page: Lisaftoclax

    lisaftolax + BTK inhibitor

  • DrugBTK inhibitor

    BTK inhibitor

06

What researchers measure

Primary outcomes

  1. PFS

    To evaluate the progression-free survival (PFS) of lisaftoclax in combination with BTKi compared with BTKi monotherapy in CLL/SLL patients previously treated with BTKi as determined by independent radiological review committee (IRC) using the iwCLL guidelines

    Time frame: 12 months

Secondary outcomes

  1. overall survival

    To evaluate overall survival (OS) of lisaftoclax in combination with BTKi versus BTKi

    Time frame: 12 months

07

Study locations

120 of 135 sites recruiting
  • Ascentage Investigative Site
    Tuscon, Arizona 85742, United States
    Recruiting
  • Ascentage Investigative Site
    Anaheim, California 92805, United States
    Recruiting
  • Ascentage Investigative Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Ascentage Investigative Site
    Miami Beach, Florida 33140, United States
    Recruiting
  • Ascentage Investigative Site
    Peoria, Illinois 61615, United States
    Recruiting
  • Ascentage Investigative Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Ascentage Investigative Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Ascentage Investigative Site
    Greenville, North Carolina 27834, United States
    Recruiting
  • Ascentage Investigative Site
    Houston, Texas 77030, United States
    Recruiting
    • Nitin Jain, MD · Principal investigator
  • Ascentage Investigative Site
    Kingswood, Texas 77339, United States
    Recruiting
  • Ascentage Investigative Site
    Richmond, Virginia 23298, United States
    Recruiting
  • Ascentage Investigative Site
    Gosford, 2250, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Ascentage Investigative Site
    Perth, 6000, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Ascentage Investigative Site
    Westmead, 2145, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Ascentage Investigative Site
    Ghent, 9000, Belgium
    Recruiting
  • Ascentage Investigative Site
    La Louvière, 7100, Belgium
    Recruiting
  • Ascentage Investigative Site
    Leuven, 3000, Belgium
    Recruiting
  • Ascentage Investigative Site
    Ottignies, 1349, Belgium
    Recruiting
  • Ascentage Investigative Site
    Roeselare, 8800, Belgium
    Recruiting
  • Ascentage Investigative Site
    Sofia, 1407, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Sofia, 1431, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Sofia, 1756, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Sofia, 1797, Bulgaria
    Recruiting
  • Ascentage Investigative Site
    Halifax, Nova Scotia B3S 0H6, Canada
    Recruiting
  • Ascentage Investigative Site
    Hefei, Anhui 230031, China
    Recruiting
  • Ascentage Investigative Site
    Beijing, Beijing Municipality 100005, China
    Recruiting
  • Ascentage Investigative Site
    Fuzhou, Fujian 350001, China
    Recruiting
  • Ascentage Investigative Site
    Foshan, Guangdong 528000, China
    Recruiting
  • Ascentage Investigative Site
    Guangzhou, Guangdong 510050, China
    Recruiting
  • Ascentage Investigative Site
    Nanning, Guangxie 530022, China
    Recruiting
  • Ascentage Investigative Site
    Zhengzhou, Henan 450003, China
    Recruiting
  • Ascentage Investigative Site
    Wuhan, Hubei 430022, China
    Recruiting
  • Ascentage Investigative Site
    Chenzhou, Hunan 423000, China
    Recruiting
  • Ascentage Investigative Site
    Nanjing, Jiangsu 210029, China
    Recruiting
  • Ascentage Investigative Site
    Suzhou, Jiangsu 215026, China
    Recruiting
  • Ascentage Investigative Site
    Wuxi, Jiangsu 214023, China
    Recruiting
  • Ascentage Investigative Site
    Nanchang, Jiangxi 330008, China
    Recruiting
  • Ascentage Investigative Site
    Xi'an, Shaanxi 710061, China
    Recruiting
  • Ascentage Investigative Site
    Binzhou, Shandong 256600, China
    Recruiting
  • Ascentage Investigative Site
    Taiyuan, Shanxi 030013, China
    Recruiting
  • Ascentage Investigative Site
    Luzhou, Sichuan 646099, China
    Recruiting
  • Ascentage Investigative Site
    Yibin, Sichuan 644099, China
    Recruiting
  • Ascentage Investigative Site
    Guangzhou, 510090, China
    Recruiting
  • Ascentage Investigative Site
    Hradec Králové, 500 05, Czechia
    Recruiting
  • Ascentage Investigative Site
    Clermont-Ferrand, 63000, France
    Recruiting
  • Ascentage Investigative Site
    Le Mans, 72037, France
    Recruiting
  • Ascentage Investigative Site
    Lyon, 69373, France
    Recruiting
  • Ascentage Investigative Site
    Nantes, 44000, France
    Recruiting
  • Ascentage Investigative Site
    Nantes, 44277, France
    Recruiting
  • Ascentage Investigative Site
    Nîmes, 30029, France
    Recruiting
  • Ascentage Investigative Site
    Orléans, 45100, France
    Recruiting
  • Ascentage Investigative Site
    Poitiers, 86000, France
    Recruiting
  • Ascentage Investigative Site
    Pontoise, 95300, France
    Recruiting
  • Ascentage Investigative Site
    Strasbourg, 67091, France
    Recruiting
  • Ascentage Investigative Site
    Tours, 37000, France
    Recruiting
  • Ascentage Investigative Site
    Dresden, 01307, Germany
    Recruiting
  • Ascentage Investigative Site
    Dresden, 48149, Germany
    Recruiting
  • Ascentage Investigative Site
    München, 81377, Germany
    Recruiting
  • Ascentage Investigative Site
    Gandhinagar, Gujarat 382428, India
    Recruiting
  • Ascentage Investigative Site
    Gurugramam, Haryana 122001, India
    Recruiting
  • Ascentage Investigative Site
    Gurugramam, Haryana 122002, India
    Recruiting
  • Ascentage Investigative Site
    Jhajjar, Haryana 124105, India
    Recruiting
  • Ascentage Investigative Site
    Bangalore, Karnataka 560027, India
    Recruiting
  • Ascentage Investigative Site
    Mysuru, Karnataka 570023, India
    Recruiting
  • Ascentage Investigative Site
    Navi Mumbai, Maharashtra 400614, India
    Recruiting
  • Ascentage Investigative Site
    Pune, Maharashtra 411001, India
    Recruiting
  • Ascentage Investigative Site
    Delhi, National Capital Territory of Delhi 110085, India
    Recruiting
  • Ascentage Investigative Site
    New Delhi, New Delhi 110017, India
    Recruiting
  • Ascentage Investigative Site
    New Delhi, New Delhi 110029, India
    Recruiting
  • Ascentage Investigative Site
    New Delhi, New Delhi 110076, India
    Recruiting
  • Ascentage Investigative Site
    New Delhi, New 110017, India
    Recruiting
  • Ascentage Investigative Site
    Madurai, Tamil Nadu 625020, India
    Recruiting
  • Ascentage Investigative Site
    Hyderabad, Telangana 500033, India
    Recruiting
  • Ascentage Investigative Site
    Kolkata, West Bengal 700014, India
    Recruiting
  • Ascentage Investigative Site
    Kolkata, West Bengal 700054, India
    Recruiting
  • Ascentage Investigative Site
    Puducherry, 605006, India
    Recruiting
  • Ascentage Investigative Site
    Haifa, 31048, Israel
    Recruiting
  • Ascentage Investigative Site
    Haifa, 3109601, Israel
    Recruiting
  • Ascentage Investigative Site
    Jerusalem, 91120, Israel
    Recruiting
  • Ascentage Investigative Site
    Kfar Saba, 4428164, Israel
    Recruiting
  • Ascentage Investigative Site
    Tel Aviv, 62431, Israel
    Recruiting
  • Ascentage Investigative Site
    Aviano, 33081, Italy
    Recruiting
  • Ascentage Investigative Site
    Brescia, 25123, Italy
    Recruiting
  • Ascentage Investigative Site
    Cona, 44124, Italy
    Recruiting
  • Ascentage Investigative Site
    Genova, 16132, Italy
    Recruiting
  • Ascentage Investigative Site
    Lecce, 73100, Italy
    Recruiting
  • Ascentage Investigative Site
    Meldola, 47014, Italy
    Recruiting
  • Ascentage Investigative Site
    Milan, 20141, Italy
    Recruiting
  • Ascentage Investigative Site
    Milan, 20132, Italy
    Recruiting
  • Ascentage Investigative Site
    Padova, 35122, Italy
    Recruiting
  • Ascentage Investigative Site
    Piacenza, 29121, Italy
    Recruiting
  • Ascentage Investigative Site
    Ravenna, 48121, Italy
    Recruiting
  • Ascentage Investigative Site
    Reggio Emilia, 42123, Italy
    Recruiting
  • Ascentage Investigative Site
    Rimini, 47923, Italy
    Recruiting
  • Ascentage Investigative Site
    Roma, 00128, Italy
    Recruiting
  • Ascentage Investigative Site
    Roma, 00168, Italy
    Recruiting
  • Ascentage Investigative Site
    Torino, 10126, Italy
    Recruiting
  • Ascentage Investigative Site
    Udine, 33100, Italy
    Recruiting
  • Ascentage Investigative Site
    Bydgoszcz, 85-048, Poland
    Recruiting
  • Ascentage Investigative Site
    Krakow, 30-727, Poland
    Recruiting

Showing the first 100 of 135 sites across 19 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Dec 20, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Oct 31, 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06104566
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Dec 20, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Shanthi Marur, MD
Contact
shanthi.marur@ascentage.com
3017925062
Yifan Zhai, MD
Contact
yzhai@ascentage.com
301-549-6188

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisaftoclax

Start the discussion